2.44
0.21%
0.005
After Hours:
2.44
OncoCyte Corporation Stock (OCX) Forecast
The OncoCyte Corporation (OCX) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $4.9367, representing a +102.32% increase from the current price of $2.44. The highest analyst price target is $5.5025, and the lowest is $4.3709.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month OCX Price Target
Average 4.7943
(+96.49% Upside)
Is OncoCyte Corporation (OCX) A Buy Now?
Oscillators
Name | Value | Action |
---|---|---|
RSI(14) | 32.06 | Neutral |
STOCH(9,6) | 35.65 | Neutral |
STOCHRSI(14) | 14.26 | Buy |
MACD(12,26) | -0.1326 | Sell |
ADX(14) | 38.32 | Sell |
William %R | -57.69 | Neutral |
CCI(14) | -113.23 | Sell |
Buy: 1
Sell: 3
Neutral: 3
Summary: Neutral
Moving Averages
Period | Simple | Exponential |
---|---|---|
MA10 |
2.5965
Sell
|
2.6053
Sell
|
MA20 |
2.7483
Sell
|
2.7183
Sell
|
MA50 |
2.9311
Sell
|
2.8706
Sell
|
MA100 |
3.03
Sell
|
2.9367
Sell
|
MA200 |
2.936
Sell
|
2.9924
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, OCX could be considered a Strong Sell, with 17 technical analysis indicators signaling 1 Buy signals, 13 signaling Sell signals and 3 Neutral signals. This might not be a good time to consider opening new positions on OCX, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 32.06 indicates that OCX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 35.65 indicates that OCX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 14.26 indicates that OCX is oversold. This suggests that OCX price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 38.32 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -113.23 indicates that OCX is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
Long-term OCX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about OncoCyte Corporation financial reports and earnings history, OncoCyte Corporation (OCX) stock could reach $13.81 by 2030, $35.88 by 2040 and $44.73 by 2050. See the projected annual prices until 2050 of the OncoCyte Corporation stock below:
- OncoCyte Corporation (OCX) is expected to reach an average price of $14.12 in 2035, with a high prediction of $14.17 and a low estimate of $13.28. This indicates an $478.81% rise from the last recorded price of $2.44.
- OncoCyte Corporation (OCX) stock is projected to chart a bullish course in 2040, with an average price target of $35.87, representing an $1,370% surge from its current level. The forecast ranges from a conservative $34.93 to a sky-high $35.88.
- Our analysts predict OncoCyte Corporation (OCX) to jump 1,577% by 2045, soaring from $40.45 to an average price of $40.93, potentially reaching $41.69. While $40.45 is the low estimate, the potential upside is significant.
- OncoCyte Corporation (OCX) stock is expected to climb by 2050, reaching an average of $44.35, a $1,718% jump from its current level. However, a wide range of estimates exists, with high and low targets of $44.73 and $43.24, respectively, highlighting the market's uncertainty.
OncoCyte Corporation Stock (OCX) Year by Year Forecast
OncoCyte Corporation Stock (OCX) Price Forecast for 2025
OncoCyte Corporation Stock (OCX) is expected to reach an average price of $4.7943 in 2025, with a high prediction of $6.6236 and a low estimate of $2.9651. This indicates an +96.49% rise from the last recorded price of $2.44.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2025 | $4.756 | $4.3709 | $5.5025 | +94.92% |
February, 2025 | $6.1061 | $4.3185 | $6.6236 | +150.25% |
March, 2025 | $4.9862 | $4.8937 | $6.3311 | +104.35% |
April, 2025 | $5.6388 | $4.7387 | $6.2612 | +131.10% |
May, 2025 | $5.5989 | $5.3239 | $5.7113 | +129.46% |
June, 2025 | $5.689 | $5.5398 | $5.754 | +133.16% |
July, 2025 | $5.5117 | $5.2217 | $6.1017 | +125.89% |
August, 2025 | $5.3629 | $5.1317 | $5.5942 | +119.79% |
September, 2025 | $3.2096 | $2.9651 | $3.98 | +31.54% |
October, 2025 | $3.3416 | $3.1302 | $3.3904 | +36.95% |
November, 2025 | $3.4743 | $3.3715 | $3.4964 | +42.39% |
December, 2025 | $3.7159 | $3.5117 | $3.7159 | +52.29% |
OncoCyte Corporation Stock (OCX) Price Forecast for 2026
The predicted value for OncoCyte Corporation (OCX) in 2026 is set at an average of $6.3291. Estimates vary from a peak of $8.9172 to a trough of $3.7409, indicating an +159.39% surge from the present price of $2.44.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2026 | $7.9461 | $3.7409 | $8.3061 | +225.66% |
February, 2026 | $7.5063 | $7.1463 | $7.9611 | +207.63% |
March, 2026 | $7.3365 | $7.2013 | $7.7864 | +200.68% |
April, 2026 | $7.4968 | $7.2156 | $7.6766 | +207.24% |
May, 2026 | $6.972 | $6.5419 | $7.5368 | +185.74% |
June, 2026 | $8.4122 | $6.557 | $8.9172 | +244.76% |
July, 2026 | $7.3374 | $7.1574 | $8.6823 | +200.71% |
August, 2026 | $8.1476 | $7.4525 | $8.7025 | +233.92% |
September, 2026 | $8.3079 | $7.8777 | $8.3129 | +240.49% |
October, 2026 | $8.4031 | $8.198 | $8.4931 | +244.39% |
November, 2026 | $8.3133 | $8.0233 | $8.9033 | +240.71% |
December, 2026 | $5.27 | $5.2301 | $8.4184 | +115.98% |
OncoCyte Corporation Stock (OCX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for OncoCyte Corporation (OCX) is $7.7854, with a high forecast of $11.22 and a low forecast of $4.3476. This indicates an +219.07% increase from the last price of $2.44.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2027 | $4.6603 | $4.3476 | $4.7003 | +91.00% |
February, 2027 | $4.8818 | $4.7123 | $4.9306 | +100.07% |
March, 2027 | $5.1781 | $4.9342 | $5.1885 | +112.22% |
April, 2027 | $5.4588 | $5.2361 | $5.4588 | +123.72% |
May, 2027 | $9.7791 | $5.5064 | $10.14 | +300.78% |
June, 2027 | $9.157 | $9.0694 | $9.8343 | +275.29% |
July, 2027 | $9.2973 | $9.2346 | $9.7546 | +281.04% |
August, 2027 | $9.6226 | $9.2739 | $9.7542 | +294.37% |
September, 2027 | $9.4955 | $8.7128 | $9.6852 | +289.16% |
October, 2027 | $10.87 | $9.4231 | $11.22 | +345.32% |
November, 2027 | $9.7561 | $9.5761 | $11.03 | +299.84% |
December, 2027 | $10.69 | $9.8937 | $11.14 | +338.28% |
OncoCyte Corporation Stock (OCX) Price Forecast for 2028
In 2028, OncoCyte Corporation (OCX) is projected to reach an average price of $8.8511, with a high projection of $11.97 and a low estimate of $5.7301. This indicates an +262.75% rise from the last price of $2.44.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2028 | $10.93 | $10.43 | $10.93 | +347.92% |
February, 2028 | $11.11 | $10.84 | $11.20 | +355.52% |
March, 2028 | $10.97 | $10.82 | $11.70 | +349.69% |
April, 2028 | $6.63 | $6.5901 | $11.25 | +171.72% |
May, 2028 | $6.2097 | $5.7301 | $6.2505 | +154.50% |
June, 2028 | $6.5025 | $6.2074 | $6.545 | +166.50% |
July, 2028 | $6.8309 | $6.5663 | $6.8413 | +179.96% |
August, 2028 | $7.2875 | $6.9114 | $7.3019 | +198.67% |
September, 2028 | $11.59 | $7.357 | $11.97 | +375.09% |
October, 2028 | $11.10 | $10.99 | $11.71 | +355.03% |
November, 2028 | $11.42 | $11.20 | $11.79 | +367.91% |
December, 2028 | $11.35 | $11.22 | $11.88 | +365.31% |
OncoCyte Corporation Stock (OCX) Price Forecast for 2029
The 2029 price forecast for OncoCyte Corporation Stock (OCX) is $10.81 on average, with a high prediction of $14.51 and a low estimate of $7.1126. This represents an +343.02% increase from the previous price of $2.44.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2029 | $13.13 | $10.88 | $13.20 | +438.28% |
February, 2029 | $12.35 | $12.23 | $13.53 | +406.33% |
March, 2029 | $13.13 | $11.99 | $13.58 | +438.32% |
April, 2029 | $13.23 | $12.97 | $13.51 | +442.02% |
May, 2029 | $13.49 | $12.99 | $13.64 | +452.70% |
June, 2029 | $14.00 | $13.60 | $14.01 | +473.62% |
July, 2029 | $13.80 | $13.63 | $14.51 | +465.44% |
August, 2029 | $7.1797 | $7.1126 | $14.14 | +194.25% |
September, 2029 | $7.6823 | $7.2455 | $7.7231 | +214.85% |
October, 2029 | $8.1563 | $7.7026 | $8.2062 | +234.27% |
November, 2029 | $8.5918 | $8.2449 | $8.6068 | +252.12% |
December, 2029 | $9.0529 | $8.6936 | $9.0673 | +271.02% |
OncoCyte Corporation Stock (OCX) Price Forecast for 2030
OncoCyte Corporation Stock (OCX) is expected to reach an average price of $12.90 in 2030, with a high forecast of $17.31 and a low forecast of $8.4952. This signifies an +428.76% surge from the last price of $2.44.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2030 | $13.35 | $9.145 | $13.81 | +447.15% |
February, 2030 | $13.43 | $12.92 | $13.69 | +450.45% |
March, 2030 | $13.48 | $13.31 | $13.85 | +452.27% |
April, 2030 | $13.50 | $13.37 | $14.01 | +453.36% |
May, 2030 | $15.40 | $13.05 | $15.47 | +530.95% |
June, 2030 | $14.71 | $14.59 | $15.84 | +502.69% |
July, 2030 | $15.68 | $14.39 | $16.03 | +542.58% |
August, 2030 | $15.80 | $15.48 | $16.00 | +547.51% |
September, 2030 | $16.13 | $15.73 | $16.28 | +561.06% |
October, 2030 | $16.71 | $16.26 | $16.80 | +584.96% |
November, 2030 | $16.71 | $16.43 | $17.31 | +584.98% |
December, 2030 | $8.5623 | $8.4952 | $17.03 | +250.91% |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):